Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

56.11 +0.99 (+1.80%)
Streaming Delayed Price Updated: 10:46 AM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023
 
Via Benzinga
US Stocks Open Lower; Dow Drops 1%
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to... 
Via Benzinga
PIXY Stock Alert: What to Know as ShiftPixy Utilizes ChatGPT for Recruiting
ShiftPixy (PIXY) stock is on the move Friday after the company announced plans to use ChatGPT for recruiting and hiring. 
Via InvestorPlace
Expert Ratings for Nektar Therapeutics
Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings: 
Via Benzinga
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
 
Via Benzinga
BA Stock Alert: Boeing Halts Deliveries of 787 Dreamliners
Boeing (BA) stock is a hot topic among traders on Friday after the aerospace company halted deliveries of its 787 Dreamliner. 
Via InvestorPlace
Why Is Nektar Therapeutics (NKTR) Stock Down 39% Today?
Nektar Therapeutics (NKTR) stock is taking a beating on Friday following the release of poor Phase 2 clinical trial data. 
Via InvestorPlace
Why Nektar Therapeutics Stock Is Plunging Today
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Gainers Cingulate Inc (NASDAQ: CING) rose 85.7% to $2.08 in pre-market trading after the company disclosed top-line results from Fed/Fast study of lead asset CTx-1301 for ADHD. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on! 
Via InvestorPlace
US Stocks Stare At More Losses In a Lackluster Week: Can Inflation Data Salvage Year's Rally?
See-sawing sentiment continues to persist on Wall Street, as index futures signal weakness on Friday after Thursday's positive close. A key inflation reading due ahead of the market opening may largely... 
Via Benzinga
BigCommerce, ContextLogic And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)
From Glancy Prongay & Murray LLP
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'
 
Via Benzinga
Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus
The major U.S. index futures are pointing to a moderately lower opening on Wall Street on Monday, as optimism following a tamer inflation data gives way to apprehension. The yield on the benchmark... 
Via Benzinga
PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics
 
Via Benzinga
Nektar Therapeutics's Return On Capital Employed Insights
Nektar Therapeutics (NASDAQ:NKTR) brought in sales totaling $21.59 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 75.97%, resulting in a loss of $159.07... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
  
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
  
Via Benzinga
Recap: Nektar Therapeutics Q2 Earnings
Nektar Therapeutics (NASDAQ:NKTR) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Nektar Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.